Alto Neuroscience Inc

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

NEW YORK CITY, NY / ACCESSWIRE / November 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Investors to Connect

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in November: Stifel 2024 Healthcare Conference, November 18-19th 2024: Format: Fireside chat and one-on-one investor meetings Presentation Date/Time:.

Alto Neuroscience to Participate in Upcoming Investor Conferences

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.

Alto Neuroscience, Inc. (ANRO) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

NEW YORK CITY, NY / ACCESSWIRE / November 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESSWIRE / November 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.

Investors Who Lost Money on Alto Neuroscience, Inc. Should Contact Levi & Korsinsky about an Ongoing Investigation - ANRO

NEW YORK CITY, NY / ACCESSWIRE / October 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Alto Neuroscience, Inc. (ANRO) Regarding Possible Securities Fraud Violations

ATTENTION ANRO SHAREHOLDERS: Investors who lost money on Alto Neuroscience, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.

Alto Neuroscience, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ANRO

ANRO ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Alto Neuroscience, Inc. Investment

NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.

Alto Neuroscience, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ANRO

LOS ANGELES, CA / ACCESSWIRE / October 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Encouraged To Contact The Schall Law Firm

Lost Money on Alto Neuroscience, Inc. (ANRO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

Alto Neuroscience, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Alto Neuroscience, Inc. (ANRO)

LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Encouraged To Help The Schall Law Firm

/ ACCESSWIRE / October 23, 2024 / NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.

Lost Money on Alto Neuroscience, Inc.(ANRO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

On Tuesday, Alto Neuroscience, Inc. ANRO revealed that the Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint compared to placebo.

Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform

LOS ANGELES , Oct. 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo. The favorable safety and tolerabili.

Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a peer-review publication demonstrating baseline cognitive performance is not a moderator of response to standard-of-care antidepressants in patients with major depressive disorder (MDD). The analysis, titled “Baseline Cognition Is Not Associated With Depression Out.

Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. “Over the recent months we achieved several important milestones for our company and for the field of precision psychiatry as a whole,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “Completing the enrollment of 301 patients in our Phase 2b study of A.

News for Alto Neuroscience Inc Stock (ANRO)